We are developing medicines that target the biological root cause of serious rare conditions to achieve disease-modification. Our lead program, apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS).
Short Bowel Syndrome
Short Bowel Syndrome affects an estimated 20,000-40,000 people in the United States and Europe and results from extensive intestinal resection due to chronic Inflammatory Bowel Disease (IBD), acute events such as trauma, mesenteric infarction, bariatric surgery or congenital abnormalities. SBS results in a malnutrition syndrome characterized by diarrhea, dehydration, weight loss, ultimately leading to the need for intravenous parenteral support that provides the nutrients and fluid supply required for survival.
To survive, patients with severe forms of SBS require parenteral support (PS), the intravenous delivery of essential nutrients, calories and fluids. For some patients, PS must be delivered for 10 to 15 hours per day and up to 7 days per week, which represents a significant burden that severely diminishes quality of life. In addition, people receiving chronic PS are exposed to increased rate of liver disease, a condition known as intestinal failure-associated liver disease, and to an increased risk of infections due to the chronic presence of an infusion port positioned in a central vein.
Apraglutide is designed for SBS patients who require chronic parenteral support.
Apraglutide is designed to increase the intestine’s ability to absorb nutrients and minimize the burden of parenteral support, thereby improving patients’ quality of life and their ability to thrive.
It is a next-generation, synthetic GLP-2 analog rationally designed to achieve an extended half-life with a synthetic manufacturing process, that has undergone extensive preclinical characterization and optimization. It has successfully completed Phase 1 single and multiple ascending dose trials in healthy volunteers. Phase 2 studies in SBS patients are currently being completed, with topline results expected in Q1 2020. Based on preclinical and clinical data to date, apraglutide has the potential to be a best-in-class treatment for SBS, with once-weekly dosing with the potential to address the specific needs of different patient types across the anatomical disease spectrum that characterizes SBS.
Our Clinical Trials
Currently, VectivBio conducts clinical research in patients with Short Bowel Syndrome. To learn about VectivBio’s future clinical trials please send your enquiry to: email@example.com